Suppr超能文献

在体外和体内具有长期增殖能力的原始急性髓系白血病细胞缺乏c-kit(CD117)的表面表达。

Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117).

作者信息

Blair A, Sutherland H J

机构信息

Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver Hospital and Health Sciences Centre, Vancouver, BC, Canada.

出版信息

Exp Hematol. 2000 Jun;28(6):660-71. doi: 10.1016/s0301-472x(00)00155-7.

Abstract

A hierarchy of progenitor cells is thought to exist in human acute myeloid leukemia (AML), with only the most primitive cells capable of proliferating to maintain the malignant clone. To further characterize this AML cell hierarchy, we evaluated the coexpression of CD34 and c-kit (CD117) on cells that are capable of long-term proliferation in vitro and in vivo.AML cells were sorted for coexpression of CD34 and c-kit (CD117) using two c-kit monoclonal antibodies (mAbs), clones 95C3 and 104D2. Sorted subfractions were evaluated for the ability to produce colony-forming units (CFU) for up to 8 weeks in suspension culture (SC) and for the capacity to repopulate NOD/SCID mice. When expression of c-kit on blood cells from 19 AML patients at diagnosis was compared using both mAbs, expression defined by 104D2 (34% +/- 6% c-kit(+)) was somewhat higher than that defined using 95C3 (18% +/- 4%). AML cells were sorted for coexpression of CD34 and c-kit using both c-kit mAbs, and the subfractions were assayed in vitro and in vivo. Whereas the majority of AML blast cells lacked expression of CD34, most AML cells capable of proliferating to produce CFU after 4 to 8 weeks in SC were CD34(+)/c-kit(-). Cultures of sorted CD34(+)/c-kit(-) cells, supplemented with steel factor, were composed of a large proportion (18% to 87%) of CD34(+)/c-kit(+) cells after 1 week, suggesting that either c-kit expression was upregulated or CD34(+)/c-kit(+) cells were produced. Moreover, the CD34(+)/c-kit(-) subfraction was found to be capable of responding to steel factor alone to produce CFU after 4 weeks in SC. In most AML patients tested (11/15), the only sorted subfraction capable of engrafting NOD/SCID mice was CD34(+)/c-kit(-). The CD34(+)/c-kit(+) subfraction from only 2 of the 15 patients and CD34(-) cells from 3 patients also engrafted the NOD/SCIDs. Only the CD34(+)/c-kit(+) subfraction of normal bone marrow engrafted. These studies suggest that primitive AML cells capable of long-term proliferation in vitro and NOD/SCID repopulation differ from primitive normal progenitor cells in their lack of surface expression of c-kit.

摘要

人们认为人类急性髓系白血病(AML)中存在祖细胞层级结构,只有最原始的细胞能够增殖以维持恶性克隆。为了进一步表征这种AML细胞层级结构,我们评估了CD34和c-kit(CD117)在体外和体内能够长期增殖的细胞上的共表达情况。使用两种c-kit单克隆抗体(mAb),即克隆95C3和104D2,对AML细胞进行CD34和c-kit(CD117)共表达的分选。对分选的亚组分进行评估,以确定其在悬浮培养(SC)中长达8周产生集落形成单位(CFU)的能力以及重建造血NOD/SCID小鼠的能力。当使用两种mAb比较19例AML患者诊断时血细胞上c-kit的表达时,由104D2定义的表达(34%±6% c-kit(+))略高于使用95C3定义的表达(18%±4%)。使用两种c-kit mAb对AML细胞进行CD34和c-kit共表达的分选,并对亚组分进行体外和体内检测。虽然大多数AML原始细胞缺乏CD34表达,但大多数在SC中培养4至8周后能够增殖产生CFU的AML细胞为CD34(+)/c-kit(-)。分选的CD34(+)/c-kit(-)细胞培养物,添加了干细胞因子,1周后由很大比例(18%至87%)的CD34(+)/c-kit(+)细胞组成,这表明要么c-kit表达上调,要么产生了CD34(+)/c-kit(+)细胞。此外,发现CD34(+)/c-kit(-)亚组分在SC中培养4周后能够单独对干细胞因子作出反应产生CFU。在大多数检测的AML患者(11/15)中,唯一能够植入NOD/SCID小鼠的分选亚组分是CD34(+)/c-kit(-)。15例患者中只有2例的CD34(+)/c-kit(+)亚组分以及3例患者的CD34(-)细胞也能植入NOD/SCID小鼠。只有正常骨髓的CD34(+)/c-kit(+)亚组分能够植入。这些研究表明,能够在体外长期增殖并重建NOD/SCID小鼠造血的原始AML细胞与原始正常祖细胞不同,其缺乏c-kit的表面表达。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验